Core Viewpoint - Mustang Bio, Inc. has successfully closed a public offering, raising approximately $8 million through the issuance of 2,657,807 shares of common stock and accompanying warrants, aimed at funding working capital and corporate purposes [1][2]. Group 1: Offering Details - The public offering included 2,657,807 shares of common stock and Series C-1 and C-2 warrants, each with an exercise price of $3.01 per share [1]. - The Series C-1 warrants will expire five years from stockholder approval, while the Series C-2 warrants will expire in twenty-four months [1]. - The gross proceeds from the offering, before fees and expenses, were approximately $8 million [2]. Group 2: Use of Proceeds - Mustang intends to utilize the net proceeds from the offering for working capital and general corporate purposes [2]. Group 3: Company Overview - Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for difficult-to-treat cancers [5]. - The company aims to acquire rights to innovative technologies and has partnered with leading medical institutions to advance CAR-T therapies [5]. - Mustang Bio's common stock is registered under the Securities Exchange Act of 1934, and it files periodic reports with the SEC [5].

Core Viewpoint - Mustang Bio, Inc. has announced a public offering of 2,657,807 shares of common stock and associated warrants at a price of $3.01 per share, aiming to raise approximately $8 million for working capital and corporate purposes [1][2]. Group 1: Offering Details - The public offering includes Series C-1 and Series C-2 warrants, each allowing the purchase of up to 2,657,807 shares at an exercise price of $3.01 [1]. - The Series C-1 warrants will expire five years from stockholder approval, while the Series C-2 warrants will expire twenty-four months from the same approval [1]. - The closing of the offering is expected around February 7, 2025, pending customary closing conditions [1]. Group 2: Financial Aspects - The gross proceeds from the offering are anticipated to be approximately $8 million before deducting fees and expenses [2]. - The net proceeds will be utilized for working capital and general corporate purposes [2]. Group 3: Company Overview - Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for difficult-to-treat cancers [5]. - The company aims to acquire rights to innovative technologies through licensing or ownership, funding research and development, and bringing these technologies to market [5]. - Mustang has established partnerships with leading medical institutions to advance CAR-T therapy development [5].

Study is the first randomized, controlled trial examining a vaccine's effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the benefit of vaccinating donors with Triplex to convey protective CMV-specific T cell immunity to allogeneic HSCT recipients at risk for CMV reactivation MIAMI, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), and its majority-owned subsidiary, Helocyte, Inc. ("Helocyte"), today a ...

Reverse Stock Split - Mustang Bio Inc announced a 1-for-50 reverse stock split of its issued and outstanding common stock, effective from January 16, 2025 [1] - The reverse stock split was approved by the Board of Directors and stockholders representing approximately 56% of the voting power on June 27, 2024 [2] - The number of outstanding shares will be reduced from approximately 64.8 million to approximately 1.3 million, with no fractional shares issued and proportional cash payments made instead [3] Compliance and Trading Details - The reverse stock split aims to bring the company into compliance with Nasdaq's $1.00 per share minimum bid price requirement for continued listing [2] - Mustang's common stock will continue to trade on Nasdaq under the symbol "MBIO" with a new CUSIP number of 62818Q302 [3] - VStock Transfer LLC is acting as the exchange and paying agent for the reverse stock split, providing instructions for physical share certificate exchanges [4] Company Overview - Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on developing cell therapies for difficult-to-treat cancers [5] - The company partners with top medical institutions to advance CAR-T therapies and aims to license or acquire technologies for research and development [5] - Mustang was founded by Fortress Biotech Inc and its common stock is registered under the Securities Exchange Act of 1934 [5]

Core Insights - The FDA has granted a six-month priority review for CUTX-101, a potential first treatment for Menkes disease, with a target action date of June 30, 2025 [1][3] - CUTX-101 has shown promising clinical efficacy, with nearly 80% reduction in the risk of death for patients receiving early treatment compared to untreated controls [2][6] - Menkes disease is a rare and fatal pediatric condition with a prevalence estimated between 1 in 34,810 to 1 in 8,664 live male births [1][8] Company Overview - Sentynl Therapeutics, a biopharmaceutical company focused on rare diseases, is responsible for the development and commercialization of CUTX-101 [4][9] - The company was acquired by Zydus Group in 2017 and aims to address unmet medical needs through innovative therapies [9][10] - Fortress Biotech, which previously advanced the CUTX-101 program, continues to support its development [5][11] Product Details - CUTX-101 is a subcutaneous injectable formulation of copper histidinate, designed to improve tolerability and enhance neurodevelopmental outcomes in Menkes disease patients [6][7] - The drug has received multiple FDA designations, including Breakthrough Therapy and Orphan Drug Designation, indicating its potential significance in treating this condition [3][6] Market Context - There are currently no FDA-approved treatments for Menkes disease, highlighting a significant unmet need in the pediatric healthcare market [8][12] - The ongoing clinical trials and positive results for CUTX-101 may position it as a critical therapeutic option for affected children and their families [2][5]

Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones Cyprium also retains ownership over any Priority Review Voucher that may be issued at NDA approval MIAMI, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced the acceptance for review of th ...

Core Insights - Fortress Biotech received FDA approval for Emrosi, a treatment for inflammatory lesions of rosacea, marking a significant milestone for the company and its partner, Journey Medical [2][3] - The company anticipates potential FDA approvals for cosibelimab by December 28, 2024, targeting metastatic or locally advanced cutaneous squamous cell carcinoma [2][3] - Fortress reported a consolidated net revenue of $14.6 million for Q3 2024, a decrease from $34.8 million in Q3 2023, primarily from marketed dermatology products [8][9] Regulatory Updates - Emrosi (Minocycline Hydrochloride Extended-Release Capsules, 40mg) was approved by the FDA in November 2024, expected to launch in early 2025 [3] - The FDA accepted the BLA resubmission for cosibelimab in July 2024, with a PDUFA goal date set for December 28, 2024 [3] - Fortress completed the asset transfer of CUTX-101 to Sentynl Therapeutics in December 2023, with a rolling submission of the NDA expected in Q4 2024 [3] Clinical Updates - Clinical data presented in October 2024 showed Emrosi provides higher dermal concentration than doxycycline, indicating a potential clinical advantage for treating rosacea [4] - Longer-term data for cosibelimab presented in September 2024 demonstrated improved response rates over time in patients with locally advanced and metastatic cSCC [4] Financial Results - As of September 30, 2024, Fortress had consolidated cash and cash equivalents of $58.9 million, down from $80.9 million at the end of 2023 [8] - Consolidated net loss attributable to common stockholders was $(15.0) million, or $(0.76) per share, for Q3 2024, compared to a net loss of $(7.1) million, or $(0.94) per share, in Q3 2023 [9][16] - Research and development expenses totaled $9.4 million for Q3 2024, significantly lower than $20.3 million in Q3 2023 [8] Commercial Product Updates - Journey Medical reported net product revenues of $14.6 million for Q3 2024, a slight decrease from $14.9 million in Q2 2024 [6] General Corporate Updates - Fortress paused dividend payments on its Series A Preferred Stock in July 2024 to maintain financial flexibility, deferring approximately $0.7 million in monthly cash payments [7] - Fortress reduced its total debt by entering a new loan agreement with Oaktree Capital Management, receiving an initial tranche of $35 million [7]

As filed with the Securities and Exchange Commission on September 27, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FORTRESS BIOTECH, INC. (Exact name of registrant as specified in its charter) Delaware 20-5157386 (State or other jurisdiction of incorporation or organization) 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 (Address, including zip code, and telephone number, inclu ...

Company Overview - Fortress Biotech, Inc. is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings, and dividend and royalty revenue [2] - The company has seven marketed prescription pharmaceutical products and over 20 programs in development across six large-market areas, including oncology, rare diseases, and gene therapy [2] - Fortress operates a streamlined structure that fosters efficient drug development and leverages significant biopharmaceutical industry expertise and networks to expand its portfolio [2] Upcoming Events - Lindsay A. Rosenwald, M.D., Chairman, President, and CEO of Fortress, will participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024, at 4:15 p.m. ET, in a virtual format [1] - Fortress will also be present at the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024, in New York, focusing on 1x1 meetings [1] - A replay of the fireside chat from the Lytham Partners conference will be available on Fortress' website for approximately 30 days following the event [1]

MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress" or "Company"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that on September 19, 2024 it entered into securities purchase agreements with healthcare focused institutional investors for the issuance and sale of 3,939,394 shares of its common stock ...